James W. Le Duc, Ph.D.
Director, Galveston National Laboratory
James W. Le Duc, Ph.D.
Galveston National Laboratory
Department of Microbiology & Immunology
Institute for Human Infections & Immunity
University of Texas Medical Branch
Galveston National Laboratory Building, Rm 6.200C
301 University Blvd.
Galveston, Texas 77555-0610
|Degree/Training Completed||Year||Name & Location|
|B.S., Zoology||1967||California State University, Long Beach|
|M.S.P.H., Infectious &
|1972||University of California, Los Angeles|
|Ph.D, Epidemiology||1977||University of California, Los Angeles|
Jim LeDuc directs the Galveston National Laboratory where basic and applied research is conducted on viruses, bacteria and rickettsia under various levels of biocontainment (BSL2, 3 and 4).
I have over four decades experience working in the fields of biodefense and public health, with leadership positions in both academia and the federal government. At present, I am the director of the Galveston National Laboratory (GNL), the largest active biocontainment facility on a US academic campus. GNL scientists are expanding a robust portfolio of research and development activities that spans from basic, discovery research to product development and evaluation, focusing on improved therapeutics, diagnostics and preventatives. We study basic disease processes to develop strategies of intervention both for specific diseases and for broad syndromes such as viral hemorrhagic fevers.
My goal as PI and director of the GNL is to ensure the safe and full utilization of the facility to advance fundamental understanding of emerging infectious diseases and threats of bioterrorism, to train the next generation of infectious disease scientists, and to contribute to the evaluation of novel products to prevent, diagnose and treat these infectious diseases using the unique containment facilities available to us. The GNL was constructed with support from NIH to assist in the national defense against emerging infectious diseases and threats of bioterrorism.
- Franz DR, LeDuc JW. Balancing Our Approach to the Insider Threat. Biosecur Bioterror. 2011 Aug 5.
- Kahlon SS, Peters CJ, LeDuc JW, Muchiri EM, Muiruri S, Njenga MK, Breiman RF, White Jr AC, King CH. Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg. 2010 Mar;82(3):371-5.
- LeDuc JW, Anderson K, Bloom ME, Carrion R Jr, Feldmann H, Fitch JP, Geisbert JB, Geisbert TW, Holbrook MR, Jahrling PB, Ksiazek TG. Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis. 2009 Jul;15(7):e1.